Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136333 | 1.00 | DRD2 (0.50) | DRD2DRD3SLC6A3KCNH2TAAR1 | |
| Hydrochloric Acid SCHEMBL29564721 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL966629 | 0.98 | — | — | |
| SCHEMBL12610007 | 0.84 | — | — | |
| SCHEMBL12610008 | 0.84 | — | — | |
| SCHEMBL15111596 | 0.81 | — | — | |
| SCHEMBL15111808 | 0.81 | — | — | |
| SCHEMBL15111597 | 0.81 | — | — | |
| SCHEMBL23472129 | 0.81 | DRD2 (0.64) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL16443901 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518939-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2193129-B1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252812-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | SANOFI-AVENTIS (FR) | 2012-10-04 | — | — | US | disclosed |
| US-8198437-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110021773-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-27 | — | — | US | disclosed |
| WO-2010104193-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-16 | — | — | WO | disclosed |
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2078717-A1 | 6-Pyrimidinyl-pyrimid-2-one derivative | sanofi-aventis (FR) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009035162-A1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008078837-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252812-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | MAPT, PSEN1, PSEN2 | DRD2 3846/4885DRD3 4206/4885SLC6A3 588/4885 |
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MAPT, TTBK1, TTBK2 | DRD2 3919/4885DRD3 3373/4885SLC6A3 2067/4885 |
| US-20110021773-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | MAPT, PSEN1, PSEN2 | DRD2 3846/4885DRD3 4206/4885SLC6A3 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.